Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Arhalofenate: Preliminary Phase II data

Preliminary data from an open-label, U.S. Phase II trial in 32 patients with gout showed that 7%, 43% (p<0.05) and 79% of patients receiving once-daily 600 mg oral arhalofenate plus 40

Read the full 317 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE